Related Experiment Video
Updated: Nov 26, 2025
08:47
Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
Published on: March 3, 2023
2.8K
MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis.
Ranny van Weissenbruch1, Ludger Klimek2, Gabriella Gálffy3
1Department of ENT Head and Neck Surgery, Wilhelmina Ziekenhuis, Assen, the Netherlands.
Journal of Asthma and Allergy
|December 9, 2020
Summary
MP-AzeFlu significantly improved allergic rhinitis symptoms and quality of life, enhancing sleep and daily activities for patients. These benefits were consistent across different patient phenotypes after 14 days of treatment.
Area of Science:
- Allergy and Immunology
- Pharmacology
- Quality of Life Research
Background:
- Allergic rhinitis (AR) significantly impacts patients' quality of life (QoL) through symptoms, sleep disturbances, and activity impairment.
- MP-AzeFlu is an established treatment for moderate-to-severe AR, but its real-world impact on QoL, particularly in immunoglobulin (Ig)E-mediated phenotypes, warrants further investigation.
Purpose of the Study:
- To evaluate the real-world effectiveness of MP-AzeFlu on sleep quality and daily activity impairment in patients with moderate-to-severe allergic rhinitis.
- To assess treatment response across different phenotypes of IgE-mediated AR.
Main Methods:
- A multicenter, prospective, non-interventional study involving patients with moderate-to-severe AR and acute symptoms (Visual Analog Scale [VAS] ≥50 mm).
- Patients received MP-AzeFlu (azelastine hydrochloride/fluticasone propionate) twice daily for approximately 14 days.
- Sleep quality and impairment in work, school, social, and outdoor activities were assessed using VAS scores.
Main Results:
- MP-AzeFlu treatment led to significant reductions in VAS scores for sleep quality (55.2 mm to 22.1 mm) and work/school impairment (57.6 mm to 23.0 mm).
- Similar improvements were noted for social activity (55.1 mm to 22.4 mm) and outdoor activity (64.4 mm to 25.0 mm) impairment.
- Treatment benefits were consistent across all evaluated VAS scores, irrespective of IgE-mediated disease phenotype, comorbidities, age, or sex.
Conclusions:
- MP-AzeFlu effectively improves patient-reported quality of life by enhancing sleep and reducing daily activity impairments in individuals with allergic rhinitis.
- The positive impact of MP-AzeFlu on QoL is consistent and not influenced by the specific phenotype of IgE-mediated allergic rhinitis.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
1.5K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.5K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.5K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.5K
01:30Asthma-IV: Diagnostic and Management
2.8K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.8K
01:24Asthma-III: Symptoms and Complications
3.0K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
3.0K
01:30Asthma-IV: Nursing Management
3.5K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
3.5K
01:20Asthma: Pathogenesis and Management
984
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
984